AI Market Mood: Stock Dashboard
HRTX
Fundamental
Company: Heron Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -0.01
Insider Own: 0.97%
Shs Outstand: 153.25M
Perf Week: 9.30%
Market Cap: 216.14M
Forward P/E: 23.50
EPS next Y: 0.06
Insider Trans: 279.36%
Shs Float: 151.81M
Perf Month: -24.19%
Enterprise Value: 352.25M
PEG: -
EPS next Q: -0.01
Inst Own: 88.73%
Short Float: 23.22%
Perf Quarter: -25.40%
Income: -0.93M
P/S: 1.44
EPS this Y: 66.67%
Inst Trans: 13.57%
Short Ratio: 21.32
Perf Half Y: -16.07%
Sales: 149.69M
P/B: -
EPS next Y Percentage: 300.00%
ROA: -0.41%
Short Interest: 35.26M
Perf YTD: -7.84%
Book/sh: -0.18
P/C: 5.32
EPS next 5Y: -
ROE: -
52W High: 2.68 -47.39%
Perf Year: -24.60%
Cash/sh: 0.27
P/FCF: -
EPS past 3/5Y: 65.87% 48.68%
ROIC: -
52W Low: 1.04 35.58%
Perf 3Y: -70.56%
Dividend Est.: -
EV/EBITDA: 93.68
Sales past 3/5Y: 18.67% -0.23%
Gross Margin: 74.61%
Volatility W: 4.70%
Volatility M: 6.72%
Perf 5Y: -90.91%
Dividend TTM: -
EV/Sales: 2.35
EPS Y/Y TTM: 98.13%
Oper. Margin: 0.96%
ATR (14): 0.10
Perf 10Y: -95.63%
Dividend Ex-Date: -
Quick Ratio: 0.53
Sales Y/Y TTM: 9.78%
Profit Margin: -0.62%
RSI (14): 38.67
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 0.82
EPS Q/Q: 74.42%
SMA20: -5.40%
Beta: 1.23
Target Price: 4.75
Payout: -
Debt/Eq: -
Sales Q/Q: 3.26%
SMA50: -22.93%
Rel Volume: 0.92
Prev Close: 1.38
Employees: 122
LT Debt/Eq: -
Earnings: Aug 08 BMO
SMA200: -23.62%
Avg Volume: 1.65M
Price: 1.41
IPO: Aug 26, 1987
Option/Short: Yes / Yes
EPS/Sales Surpr.: -100.00% -2.30%
Trades:
Volume: 1,522,841
Change: 2.17%
Technical:
Latest News:
Heron Therapeutics (NASDAQ:HRTX) Earns Overweight Rating from Analysts at Capital ... somewhat bullish
HRTX
Summary: Capital One Financial initiated coverage on Heron Therapeutics with an overweight rating and a $6.00 price target. Other research analysts have also issued positive ratings for the company. Heron Therapeutics recently reported better-than-expected quarterly earnings. Institutional investors have shown interest in the company.
Full article2024-04-24T18:45:09Z
Capital One Initiates Coverage of Heron Therapeutics (HRTX) with Overweight Recommendation very bullish
HRTX
Summary: Capital One initiated coverage of Heron Therapeutics (NasdaqCM:HRTX) with an Overweight recommendation and a projected 175.68% upside in the stock price. Multiple institutional investors hold significant amounts of shares in Heron Therapeutics.
Full article2024-04-24T00:06:43Z